NRX Change In Working Capital from 2010 to 2025

NRXP Stock  USD 2.07  0.10  4.61%   
NRX Pharmaceuticals Change In Working Capital yearly trend continues to be relatively stable with very little volatility. Change In Working Capital is likely to grow to about 6.2 M this year. Change In Working Capital is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. View All Fundamentals
 
Change In Working Capital  
First Reported
2017-12-31
Previous Quarter
M
Current Value
43 K
Quarterly Volatility
M
 
Covid
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 372.8 K, Interest Expense of 131.1 K or Selling General Administrative of 20.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRX Pharmaceuticals Correlation against competitors.
To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.

Latest NRX Pharmaceuticals' Change In Working Capital Growth Pattern

Below is the plot of the Change In Working Capital of NRX Pharmaceuticals over the last few years. It is the difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities. NRX Pharmaceuticals' Change In Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Change In Working Capital10 Years Trend
Slightly volatile
   Change In Working Capital   
       Timeline  

NRX Change In Working Capital Regression Statistics

Arithmetic Mean1,070,986
Coefficient Of Variation263.18
Mean Deviation2,063,398
Median(1,331)
Standard Deviation2,818,603
Sample Variance7.9T
Range11.1M
R-Value0.54
Mean Square Error6T
R-Squared0.29
Significance0.03
Slope319,791
Total Sum of Squares119.2T

NRX Change In Working Capital History

20256.2 M
20245.9 M
20235.2 M
2022699 K
2021-4.9 M
20203.5 M
2019 4662.0

About NRX Pharmaceuticals Financial Statements

NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Change In Working Capital, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Working Capital5.9 M6.2 M

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.